These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 23087429)

  • 21. Evaluation on the persistence of anti-HPV immune responses to the quadrivalent HPV vaccine in Chinese females and males: Up to 3.5 years of follow-up.
    Huang T; Liu Y; Li Y; Liao Y; Shou Q; Zheng M; Liao X; Li R
    Vaccine; 2018 Mar; 36(11):1368-1374. PubMed ID: 29428178
    [TBL] [Abstract][Full Text] [Related]  

  • 22. HPV vaccine continues to be safe and effective, and its benefits continue to outweigh its risks.
    Haupt RM; Sattler C
    Expert Rev Vaccines; 2010 Jul; 9(7):697-701. PubMed ID: 20624041
    [No Abstract]   [Full Text] [Related]  

  • 23. Quadrivalent Human Papillomavirus Vaccine: Recommendations of the Advisory Committee on Immunization Practices (ACIP).
    Markowitz LE; Dunne EF; Saraiya M; Lawson HW; Chesson H; Unger ER; ;
    MMWR Recomm Rep; 2007 Mar; 56(RR-2):1-24. PubMed ID: 17380109
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Fall in human papillomavirus prevalence following a national vaccination program.
    Tabrizi SN; Brotherton JM; Kaldor JM; Skinner SR; Cummins E; Liu B; Bateson D; McNamee K; Garefalakis M; Garland SM
    J Infect Dis; 2012 Dec; 206(11):1645-51. PubMed ID: 23087430
    [TBL] [Abstract][Full Text] [Related]  

  • 25. HPV vaccines: Translating immunogenicity into efficacy.
    Turner TB; Huh WK
    Hum Vaccin Immunother; 2016 Jun; 12(6):1403-5. PubMed ID: 26512762
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Immunogenicity of quadrivalent HPV vaccine among girls 11 to 13 Years of age vaccinated using alternative dosing schedules: results 29 to 32 months after third dose.
    Lamontagne DS; Thiem VD; Huong VM; Tang Y; Neuzil KM
    J Infect Dis; 2013 Oct; 208(8):1325-34. PubMed ID: 23901077
    [TBL] [Abstract][Full Text] [Related]  

  • 27. HPV 16/18 prevalence reduced 3 years following vaccine introduction.
    Riedmann EM
    Hum Vaccin Immunother; 2014; 10(2):254. PubMed ID: 24963520
    [No Abstract]   [Full Text] [Related]  

  • 28. One in four California adolescent girls have had human papillomavirus vaccination.
    Grant D; Kravitz-Wirtz N; Breen N; Tiro JA; Tsui J
    Policy Brief UCLA Cent Health Policy Res; 2009 Feb; (PB2009-3):1-6. PubMed ID: 19288623
    [No Abstract]   [Full Text] [Related]  

  • 29. Comparative immunogenicity and safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine and HPV-6/11/16/18 vaccine administered according to 2- and 3-dose schedules in girls aged 9-14 years: Results to month 12 from a randomized trial.
    Leung TF; Liu AP; Lim FS; Thollot F; Oh HM; Lee BW; Rombo L; Tan NC; Rouzier R; Friel D; De Muynck B; De Simoni S; Suryakiran P; Hezareh M; Folschweiller N; Thomas F; Struyf F
    Hum Vaccin Immunother; 2015; 11(7):1689-702. PubMed ID: 26062002
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Reply to Harper.
    LaMontagne DS
    J Infect Dis; 2014 Jul; 210(2):331-2. PubMed ID: 24501213
    [No Abstract]   [Full Text] [Related]  

  • 31. Impact of baseline covariates on the immunogenicity of a quadrivalent (types 6, 11, 16, and 18) human papillomavirus virus-like-particle vaccine.
    Giuliano AR; Lazcano-Ponce E; Villa L; Nolan T; Marchant C; Radley D; Golm G; McCarroll K; Yu J; Esser MT; Vuocolo SC; Barr E
    J Infect Dis; 2007 Oct; 196(8):1153-62. PubMed ID: 17955433
    [TBL] [Abstract][Full Text] [Related]  

  • 32. HPV prevention and the promise of the new vaccines.
    Allred S; Cox JT; Mahoney M
    J Am Acad Nurse Pract; 2006; 18 Suppl 2():1-11. PubMed ID: 17474243
    [No Abstract]   [Full Text] [Related]  

  • 33. Uptake of the human papillomavirus vaccine: a review of the literature and report of a quality assurance project.
    Cassidy B; Schlenk EA
    J Pediatr Health Care; 2012 Mar; 26(2):92-101. PubMed ID: 22360928
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Considerations for human papillomavirus (HPV) vaccination of mid-adult women in the United States.
    Grant LA; Dunne EF; Chesson H; Markowitz LE
    Vaccine; 2011 Mar; 29(13):2365-70. PubMed ID: 21277406
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effect of a group educational intervention on rural Chinese women's knowledge and attitudes about human papillomavirus (HPV) and HPV vaccines.
    Li J; Kang LN; Li B; Pang Y; Huang R; Qiao YL
    BMC Cancer; 2015 Oct; 15():691. PubMed ID: 26467534
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Introduction. The human papillomavirus VLP vaccines.
    Stanley M
    Gynecol Oncol; 2010 Jun; 118(1 Suppl):S1. PubMed ID: 20494218
    [No Abstract]   [Full Text] [Related]  

  • 37. Introducing HPV vaccine in developing countries--key challenges and issues.
    Agosti JM; Goldie SJ
    N Engl J Med; 2007 May; 356(19):1908-10. PubMed ID: 17494923
    [No Abstract]   [Full Text] [Related]  

  • 38. [Bulletin INFOVAC-France].
    Cohen R; Bakhache P; Bégué P; Besse P; Dommergues MA; Dufour V; Floret D; Garnier JM; Gaudelus J; Grimprel E; Guérin N; Hau I; Pinquier D; Reinert P; Romain O; Thiebault G; Vié le Sage F; Virey B; Weil-Olivier C; Siegrist CA
    Arch Pediatr; 2011 Oct; 18(10):1124-5. PubMed ID: 22059239
    [No Abstract]   [Full Text] [Related]  

  • 39. Moving forward: human papillomavirus vaccination and the prevention of cervical cancer.
    Vetter KM; Geller SE
    J Womens Health (Larchmt); 2007 Nov; 16(9):1258-68. PubMed ID: 18001182
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Monitoring the impact of HPV vaccine in males-Considerations and challenges.
    Brotherton JML; Giuliano AR; Markowitz LE; Dunne EF; Ogilvie GS
    Papillomavirus Res; 2016 Dec; 2():106-111. PubMed ID: 29074169
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.